Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  Tiziani, Stefano ^a   Kang, Yunyi ^a   Choi, Janet S ^a   Roberts, William ^b   Paternostro, Giovanni ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE; ASPARAGINASE; BIM 0050229; BIM 0086749; BIM 0086751; BIM 0086768; BIM 0086775; BIM 0086776; BIM 0207152; BIM 0207163; DEXAMETHASONE; DICHLOROACETIC ACID; GLUCOSE; I KAPPA B; LACTIC ACID; METHIONINE; PHOSPHOTRANSFERASE INHIBITOR; PYRUVIC ACID; RAPAMYCIN; UNCLASSIFIED DRUG; VINCRISTINE; PROTEIN KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LOW DRUG DOSE; MAMMAL CELL; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OVARY CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; VALIDATION STUDY; CELL LINE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN KINASE INHIBITORS;

EID: 82555186342     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1562     Document Type: Article

References (60)

1. Duarte, I. F. et al. Analytical approaches toward successful human cell metabolome studies by NMR spectroscopy. Anal. Chem. 81, 5023-5032 (2009).
2. Abraham, V. C., Taylor, D. L. & Haskins, J. R. High content screening applied to large-scale cell biology. Trends Biotechnol. 22, 15-22 (2004). (Pubitemid 38030316)
3. Baker, M. Academic screening goes high-throughput. Nat. Methods 7, 787-792 (2010).
4. Neumann, B. et al. High-throughput RNAi screening by time-lapse imaging of live human cells. Nat. Methods 3, 385-390 (2006).
5. Zanella, F., Lorens, J. B. & Link, W. High content screening: seeing is believing. Trends Biotechnol. 28, 237-245 (2010).
6. Bradley, S. A. et al. Fermentanomics: monitoring mammalian cell cultures with NMR spectroscopy. J. Am. Chem. Soc. 132, 9531-9533 (2010).
7. Dietmair, S., Timmins, N. E., Gray, P. P., Nielsen, L. K. & Kromer, J. O. Towards quantitative metabolomics of mammalian cells: development of a metabolite extraction protocol. Anal. Biochem. 404, 155-164 (2010).
8. Kell, D. B. et al. Metabolic footprinting and systems biology: the medium is the message. Nat. Rev. Microbiol. 3, 557-565 (2005). (Pubitemid 40908875)
9. Sellick, C. A. et al. Effective quenching processes for physiologically valid metabolite profiling of suspension cultured mammalian cells. Anal. Chem. 81, 174-183 (2009).
10. Wu, H. F., Southam, A. D., Hines, A. & Viant, M. R. High-throughput tissue extraction protocol for NMR and MS-based metabolomics. Anal. Biochem. 372, 204-212 (2008). (Pubitemid 350116777)
11. Fischer, E. & Sauer, U. Metabolic flux profiling of Escherichia coli mutants in central carbon metabolism using GC-MS. Eur. J. Biochem. 270, 880-891 (2003). (Pubitemid 36315331)
12. Ewald, J. C., Heux, S. & Zamboni, N. High-throughput quantitative metabolomics: workflow for cultivation, quenching, and analysis of yeast in a multiwell format 81, 3623-3629 (2009).
13. Kummel, A. et al. Integration of multiple readouts into the Z? factor for assay quality assessment. J. Biomol. Screen 15, 95-101 (2010).
14. Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24, 167-175 (2006). (Pubitemid 43221699)
15. Zhang, J. H., Chung, T. D. Y. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67-73 (1999). (Pubitemid 29278954)
16. Blower, P. E. et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6, 1483-1491 (2007). (Pubitemid 46954015)
17. Avramis, V. I. & Tiwari, P. N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int. J. Nanomed. 1, 241-254 (2006).
18. Pui, C. H., Campana, D. & Evans, W. E. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol. 2, 597-607 (2001). (Pubitemid 32998539)
19. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002). (Pubitemid 37361447)
20. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002). (Pubitemid 35425239)
21. Gottschalk, S., Anderson, N., Hainz, C., Eckhardt, S. G. & Serkova, N. J. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin. Cancer Res. 10, 6661-6668 (2004). (Pubitemid 39346563)
22. Griffin, J. L. & Shockcor, J. P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 4, 551-561 (2004). (Pubitemid 38868624)
23. Hsu, P. P. & Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703-707 (2008).
24. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
25. Beloueche-Babari, M. et al. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 65, 3356-3363 (2005). (Pubitemid 40524620)
26. Lodi, A. et al. Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. ACS Chem. Biol. 6, 169-175 (2011).
27. Romanska, H. M. et al. Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts. Neoplasia 11, 1301 (2009).
28. Tiziani, S. et al. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines 4, e4251 (2009).
29. Shushan, B. A review of clinical diagnostic applications of liquid chromatography-tandem mass spectrometry. Mass Spectrom. Rev. 29, 930-944 (2010).
30. Howell, S. C., Mesleh, M. F. & Opella, S. J. NMR structure determination of a membrane protein with two transmembrane helices in micelles: MerF of the bacterial mercury detoxification system. Biochemistry 44, 5196-5206 (2005). (Pubitemid 40471234)
31. Evans, R., Haiber, S., Nilsson, M. & Morris, G. A. Isomer resolution by micelle-assisted diffusion-ordered spectroscopy. Anal. Chem. 81, 4548-4550 (2009).
32. Raftery, D. High-throughput NMR spectroscopy. Anal. Bioanal. Chem. 378, 1403-1404 (2004). (Pubitemid 40877673)
33. Mercier, P., Lewis, M. J., Chang, D., Baker, D. & Wishart, D. S. Towards automatic metabolomic profiling of high-resolution one-dimensional proton NMR spectra. J. Biomol. NMR 49, 307-323 (2011).
34. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
35. Harrington, L. S., Findlay, G. M. & Lamb, R. F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30, 35-42 (2005). (Pubitemid 40093739)
36. Heiden, M. G. V. et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499 (2010).
37. Larach D. B., Kofke, W. A. & Le Roux, P. Potential non-hypoxic/ischemic causes of increased cerebral interstitial fluid lactate/pyruvate ratio: a review of available literature. Neurocrit Care 1-14 2011
38. DePinieux, G. et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio 42, 333-337 (1996).
39. Yang, L. L. et al. Metabolomic and mass isotopomer analysis of liver gluconeogenesis and citric acid cycle-II. Heterogeneity of metabolite labeling pattern. J. Biol. Chem. 283, 21988-21996 (2008).
40. Bain, J. R. et al. Metabolomics applied to diabetes research moving from information to knowledge. Diabetes 58, 2429-2443 (2009).
41. Feala, J. D. et al. Systems approaches and algorithms for discovery of combinatorial therapies. Rev. Syst. Biol. Med. 2, 181-193 (2010).
42. Bollenbach, T. & Kishony, R. Resolution of gene regulatory conflicts caused by combinations of antibiotics. Mol. Cell. 42, 413-425 (2011).
43. Geva-Zatorsky, N. et al. Protein dynamics in drug combinations: a linear superposition of individual-drug responses. Cell 140, 643-651 (2010).
44. Calzolari D. et al. Search algorithms as a framework for the optimization of drug combinations. PLoS Comput. Biol. 4:2008
45. Arora, S. et al. Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 63, 6894-6899 (2003). (Pubitemid 37322973)
46. Kane, L. P., Shapiro, V. S., Stokoe, D. & Weiss, A. Induction of NF-kappa B by the Akt PKB kinase. Curr. Biol. 9, 601-604 (1999). (Pubitemid 29273109)
47. Cheng Y. et al. Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS One 5:2010
48. Clayton, T. A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
49. Serkova, N. J., Spratlin, J. L. & Eckhardt, S. G. NMR-based metabolomics: translational application and treatment of cancer. Curr. Opin. Mol. Ther. 9, 572-585 (2007). (Pubitemid 350179097)
50. Beckonert, O. et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2, 2692-2703 (2007).
51. Aue, W., Karhan, J. & Ernst, R. Homonuclear broad-band decoupling and 2-dimensional J-resolved NMR spectroscopy. J. Chem. Phys. 64, 4226-4227 (1976).
52. Thrippleton, M. J., Edden, R. A. E. & Keeler, J. Suppression of strong coupling artefacts in J-spectra. J. Magn. Reson. 174, 97-109 (2005). (Pubitemid 40423613)
53. Hwang, T. L. & Shaka, A. J. Water suppression that works-excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J. Magn. Reson. Ser. A 112, 275-279 (1995).
54. Tiziani, S., Lodi, A., Ludwig, C., Parsons, H. M. & Viant, M. R. Effects of the application of different window functions and projection methods on processing of H-1 J-resolved nuclear magnetic resonance spectra for metabolomics. Anal. Chim. Acta 610, 80-88 (2008).
55. Gunther, U. L., Ludwig, C. & Ruterjans, H. NMRLAB-advanced NMR data processing in MATLAB. J. Magn. Reson. 145, 201-208 (2000).
56. Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in H-1 NMR metabonomics. Anal. Chem. 78, 4281-4290 (2006).
57. Parsons, H. M., Ludwig, C., Gunther, U. L. & Viant, M. R. Improved classification accuracy in 1-and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation. BMC Bioinformatics 8 (2007).
58. Cui, Q. et al. Metabolite identification via the madison metabolomics consortium database. Nat. Biotechnol. 26, 162-164 (2008). (Pubitemid 351225941)
59. Wishart, D. S. et al. HMDB: the human metabolome database. Nucleic Acids Res. 35, D521-D526 (2007). (Pubitemid 46056263)
60. Wold, S., Esbensen, K. & Geladi, P. Principal component analysis. Chemom. Intell. Lab. Syst. 2, 37 (1987).